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INTRODUCTION
Histopathologic observations and the examination of
bronchoalveolar lavage (BAL) fluid from patients and
experimental animals with fibrotic lung disease suggest
that the blood coagulation system is activated in the
course of pulmonary fibrosis (1-7). Histologically, fibrin is
observed in the interstitium and the alveolar surface of
patients with idiopathic pulmonary fibrosis (IPF) or adult
respiratory distress syndrome (ARDS) (1, 3, 4), and the
sites of early fibrin deposition correlate with the location
of subsequent fibrotic processes in these disorders (2).
Additionally, increased procoagulant activity is observed
in the BAL fluid from patients with IPF or ARDS and from
animal models of bleomycin-induced lung injury (5-7).
Thus, the activation of blood coagulation may have an
influence on the development of pulmonary fibrosis.
Thrombin, which is involved in blood clotting, is a
multifunctional enzyme generated during vascular injury.
This enzyme has been shown to stimulate the growth
of a variety of cell types, including fibroblasts (8-10),
macrophage-like cells (11, 12), monocytes (13), and T
lymphocytes (14). We previously observed an increased
activity level of thrombin in the BAL fluid from rats with
bleomycin-induced lung injury, which was responsible for
the development of pulmonary fibrosis and served as a
growth-stimulating factor for fibroblasts (15). Ohba et al.
recently reported that the level of thrombin activity in
BAL fluid from patients with scleroderma was higher than
in normal controls, and that thrombin was responsible for
fibroblast growth in this disorder (16).
In the present study, we focused on evidence that
thrombin stimulates alveolar macrophages (AM) to re-
lease cytokines, and we obtained the first direct evidence
that thrombin stimulates the production of platelet-derived
growth factor (PDGF) by AM.
MATERIALS AND METHODS
Administration of Bleomycin
Male Wistar rats (Tokushima Experimental Animal
Laboratories, Tokushima, Japan) weighing 170-190 g were
used. They were lightly anesthetized with an intraperito-
neal injection of sodium pentobarbital (10 mg) and given a
single intratracheal injection of 0.6 mg of bleomycin
sulfate (Nippon Kayaku Co., Tokyo, Japan) dissolved in
0.3 ml of sterile saline. Control rats received 0.3 ml of
sterile saline alone by the same route.
Stimulation of AM and Preparation of AM Supernatants
The lungs were removed with other thoracic organs
from the control and bleomycin-treated rats on day 4 after
treatment. The trachea was cannulated with a plastic
Thrombin stimulates platelet-derived growth factor
release by alveolar macrophages in rats -significance
in bleomycin-induced pulmonary fibrosis-
Kenji Tani, Fumitaka Ogushi, Hiroko Takahashi, Tetsuya Kawano,Takeshi Endo
and Saburo Sone
Third Department of Internal Medicine, The University of Tokushima School of Medicine, Tokushima, Japan
Abstract : Thrombin is a multifunctional enzyme generated at sites of vascular injury, and is known
to be increased in the lungs in some types of fibrotic lung disease. In this study, to determine whether
thrombin is associated with fibroblast growth and pulmonary fibrosis in these disorders, we
examined whether a growth factor for fibroblasts (platelet-derived growth factor, PDGF) was
released by thrombin-stimulated alveolar macrophages (AM). The culture supernatants of rat AM
stimulated with 1 or 10 U/ml of thrombin showed a significant increase in fibroblast growth-
stimulating activity (FGA). Pretreatment of the AM supernatant with anti-PDGF-AA antibody
significantly decreased the FGA, but pretreatment with anti-PDGF-BB antibody did not. The
supernatants of AM stimulated with thrombin also increased the growth of fibroblasts from the lungs
of rats with bleomycin-induced lung injury. These results indicate that thrombin stimulates AM to
release PDGF-AA, which is responsible, at least in part, for fibroblast growth and the development of
pulmonary fibrosis in some types of fibrotic lung disease. J. Med. Invest. 44 : 59-65, 1997
Key Words : thrombin, fibroblast growth-stimulating factor, platelet-derived growth factor, pulmonary fibrosis
Received for publication June 30, 1997 ; accepted July 16, 1997.
１ Address correspondence and reprint requests to Kenji Tani, M.D.,
Ph.D., Third Department of Internal Medicine, The University of Tokushima
School of Medicine, 3-18-15, Kuramoto-cho, Tokushima, Japan.
The Journal of Medical Investigation Vol.44 1997
５９
catheter attached to a 10-ml syringe, and BAL was
performed with a total volume of 25 ml of sterile saline in
five 5-ml portions. The BAL cells were pelleted by
centrifugation at 250 x g for 10 min and washed 3 times
with Dulbecco's modified Eagle medium (DMEM ; Nissui
Pharmaceutical Co., Tokyo) containing penicillin (100 U/
ml) and streptomycin (100 μg/ml), and then resuspended
in DMEM. The total cell count of the suspension was
determined in a hemocytometer, and differential cell
counts were determined by a cytocentrifugation of the
cells. AM were seeded at a density of 1 x 106 cells/ml in
24-well multiwell plates (Falcon 3047 ; Falcon Plastics, Ox-
nard, CA). After culturing for 1 h at 37℃ in a humidified
atmosphere of 5% CO2 in air, the plates were washed three
times to remove non-adherent cells. The AM cell layers
were cultured with (1) medium alone [DMEM containing
bovine serum albumin (BSA ; Sigma Chemical Co., St.
Louis, MO)], (2) medium + purified rat thrombin (Sigma,1
U/ml or 10 U/ml), and (3) medium + lipopolysaccharide
(LPS,1 μg/ml). The total volume of all AM cultures was
1 ml/well, and the final concentration of BSA was
1%. After culturing for 24 h at 37℃ in a humidified
atmosphere of 5% CO2 in air, the AM supernatants were
sterilized by micropore filtration (0.45-μm-pore filters ;
Millipore Corp., Bedford, MA) and stored at -70℃. The
viability of the AM, as determined by trypan blue
exclusion prior to and after their incubation, was always
greater than 95%.
In Vitro Effects of AM Supernatants on Fibroblast Growth
Lung fibroblasts from control and bleomycin-treated
rats on day 4 after treatment were obtained by the method
of Phan et al. (17). Unless otherwise stated, lung fibro-
blasts from control rats were used in this study.
Fibroblasts between the fifth and tenth passages were
used. Fibroblasts harvested from culture dishes by
trypsinization were suspended in DMEM containing 10%
fetal calf serum (FCS ; GIBCO, Grand Island, NY). Fibro-
blasts were seeded at a density of 1 x 104 cells/200 μl/well
in 96-well multiwell plates (Falcon 3072). After culturing
for 24 h at 37℃ in a humidified atmosphere of 5% CO2 in
air, each well was washed three times with DMEM, and
then fibroblasts were cultured in DMEM without serum at
37℃ in a humidified atmosphere of 5% CO2 in air. After
culturing for 24 h, the medium was removed, and the AM
supernatants from control or bleomycin-treated rats were
added with DMEM containing BSA in a total volume of
200 μl/well. The final concentration of BSA in all fibro-
blast cultures was 1%, and all experiments were done in
triplicate. DMEM containing 1% BSA was used as a
control of the AM supernatants (medium control). After
further culture for 3 days at 37℃ in a humidified atmos-
phere of 5% CO2 in air, the fibroblast growth-stimulating
activity (FGA) of the AM supernatants was determined by
the viable cell-staining method as reported previously (15,
18). Briefly, the medium was removed, the plates were
washed twice with phosphate-buffered saline, and the
remaining viable adherent fibroblasts were stained with
100 μl of crystal violet solution (0.3% in 2% ethanol) for 20
min at 37℃. The crystal violet solution was then removed,
and the plates were washed with distilled water. The
stained cells were solubilized in 100 μl of 2% sodium
dodecyl sulfate, and the absorbance at 550 nm of each
well was measured with a model MTP-12 Microplate
Photometer (Corona Electric Co., Tokyo). In preliminary
experiments, this cell-staining method showed a close
correlation with the viable cell number and 3H-thymidine
incorporation, as reported previously (15).
Effects of Anti-PDGF Antibodies on the FGA of AM
Supernatants
Anti-human PDGF antibodies were purchased from
Wako Chemical Co., Osaka, Japan. The supernatant of
control rat AM treated with 1 U/ml of rat thrombin was
preincubated with an equal volume of anti-PDGF-AA or
anti-PDGF-BB antibody solution (500 or 5,000 ng/ml) at
4℃ for 16 h. The solutions were then tested on fibroblasts
for FGA as described above.
Effect of Argatroban on the FGA in AM Supernatants
We examined the effect of argatroban on the FGA in the
supernatant of control rat AM treated with thrombin.
Argatroban was a generous gift from Mitsubishi Kasei
Corp., Tokyo. This synthetic arginine derivative is known
to be a potent and highly specific thrombin inhibitor (19-
21). The supernatant of control rat AM treated with 1 U/
ml of rat thrombin was preincubated with an equal volume
of argatroban solution (100 μM) at 37℃ for 3 h. The
solutions were then tested on fibroblasts for FGA as
described above.
Effects of PDGF-AA and -BB on Fibroblast Growth
Fibroblasts were cultured with various concentrations
of recombinant human PDGF-AA or- BB (Wako) in
DMEM containing BSA or FCS in a total volume of
200 μl/well at 37℃ in a humidified atmosphere of 5% CO2
in air. After culturing for 3 days, FGA was determined as
described above.
Measurement of Interleukin-1 in AM Supernatants
Enzyme immunoassays for rat interleukin (IL)-1 α and
IL-1 β were performed as described previously (22, 23).
The sensitivity units of the enzyme immunoassays for IL-
1 α and IL-1 β were 20 and 2,000 pg/ml, respectively.
Statistical Analysis
All results are expressed as mean±SD. Statistical
significance was determined by Student's t test, and a p
value of <0.05 was considered significant.
RESULTS
Fibroblast Growth-Stimulating Activity in AM Supernatants
The supernatants of AM from control rats were added
to the cultures of fibroblasts from the lungs of control and
bleomycin-treated rats at a concentration of 10%, and the
FGA was then measured (Fig.1). The FGA was expressed
as the percentage increase from the value in the medium
control cultures. The supernatants from untreated or LPS-
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treated AM had no effect on the growth of fibroblasts from
control rats. In contrast, the supernatants of AM treated
with 1 U/ml and 10 U/ml thrombin showed significant
increases in FGA (52.2±7.5% and 79.3±25.9%, respec-
tively). The supernatants of AM treated with 1 U/ml and
10 U/ml of thrombin also stimulated the growth of
fibroblasts from bleomycin-treated rats (51.9±8.5% FGA
and 53.3±14.4% FGA, respectively), similar to that of
control fibroblasts .
Effects of Anti-PDGF Antibodies on the FGA in AM
Supernatants
We examined the effects of anti-PDGF antibodies on the
FGA detected in the supernatant of AM treated with 1 U/
ml thrombin (Fig.2). The pretreatment of the AM
supernatant with anti-PDGF-AA antibody (250 U/ml and
2500 U/ml) significantly decreased the FGA (by 54.8%
and 85.5%, respectively). The pretreatment with anti-
PDGF-BB antibody did not decrease the FGA in the AM
supernatant. The anti-PDGF-AA and -BB antibodies them-
selves at the concentrations used in this experiment had
no effect on fibroblast growth (data not shown).
Effect of Argatroban on the FGA in AM Supernatants
Thrombin itself is known to stimulate fibroblast growth.
Thus, the effect of argatroban on the FGA in AM
supernatants was examined to determine whether the
FGA in the AM supernatants was due to thrombin
Fig.1. Fibroblast growth-stimulating activity (FGA) in the super-
natants of AM from control rats, cultured with medium alone,
medium + LPS (1 μg/ml), or medium + purified rat thrombin (1 U/
ml or 10 U/ml) for 24 h. Samples of the AM supernatants were
added to cultures of fibroblasts from the lungs of control and
bleomycin-treated rats at a concentration of 10%. After culturing for
3 days, their effects on fibroblast growth were assayed as described
in Materials and Methods. The FGA is expressed as the percentage
increases from the value of the medium control culture. Columns
and bars show means and SD of values for three rats.
*Significantly different from the value cultured in medium alone by
Student's t-test (p<0.01).
Fig. 3. The effect of argatroban on the FGA in AM supernatants.
The supernatants from control rat AM treated with 1 U/ml of
thrombin and thrombin solutions (1 U/ml) were preincubated with
an equal volume of argatroban (100 μM) at 37℃ for 3 h. The
solutions were then added to cultures of fibroblasts from control
rats. After culturing for 3 days, their effects on fibroblast growth
were assayed as described in Materials and Methods. The FGA is
expressed as the percentage increase from the value of the medium
control culture. Columns and bars show the means and SD of
values for 3 rats.
Fig. 2. The effects of anti-PDGF-AA and -BB antibodies on the
FGA in AM supernatants. The supernatants from control rat AM
treated with 1 U/ml of thrombin were preincubated with an equal
volume of anti-PDGF-AA or -BB antibody solution (500 or 5,000 ng/
ml) at 4℃ for 16 h. The solutions were then added to fibroblast
cultures containing 10% AM supernatants. After culturing for 3
days, their effects on fibroblast growth were assayed as described
in Materials and Methods. The FGA is expressed as the percentage
increase from the value of the medium control culture. Columns
and bars show the means and SD of values for 3 rats.
*Significantly different from the value cultured in AM supernatant
not treated with PDGF antibodies by Student's t-test (p<0.01)
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remaining in the supernatant (Fig.3). By pretreatment
with argatroban, the FGA of purified rat thrombin
decreased to 10.6±3.0%. In contrast, the pretreatment of
the supernatant of thrombin-treated AM with argatroban
decreased the FGA only to 81.9±2.5%. Argatroban itself at
the concentration used in this experiment did not affect
fibroblast growth (data not shown). These results indi-
cated that the FGA in the AM supernatant was different
from the activity of thrombin remaining in the superna-
tant.
Fibroblast Growth-Stimulating Activity by Human PDGF
The in vitro effects of recombinant human PDGF-AA
and -BB on fibroblast growth were examined in various
serum conditions (Fig.4). Lung fibroblasts from control
rats were observed to respond to human plasma-derived
PDGF in a cell proliferation assay(24). Our study showed
that human PDGF-AA and -BB stimulated rat fibroblast
growth in a dose-dependent manner. Although the FGA of
PDGF was found in fibroblast cultures both with and
without serum, in the presence of 1% and 2% FCS, the
FGA of PDGF-BB was greater than that of PDGF-AA. In
serum-free medium (1% BSA alone), PDGF-AA showed a
proliferative effect on fibroblasts slightly higher than that
of PDGF-BB.
The Effects of the Supernatants of AM from Bleomycin-
Treated Rats on Fibroblast Growth
The effects of the supernatants of AM from bleomycin-
treated rats on the growth of fibroblasts from the lungs of
control and bleomycin-treated rats are shown in Fig.5.
The supernatant from the untreated AM of bleomycin-
treated rats showed an inhibitory activity on the growth of
fibroblasts from the lungs of control rats (-31.5±4.5%).
LPS significantly increased the inhibitory activity(-47.7±
4.8%). The supernatants of untreated and LPS-treated AM
also showed inhibitory activity on the fibroblasts from the
lungs of bleomycin-treated rats, but this inhibitory activity
was higher than that seen in control fibroblasts (un-
treated ; -50.8±11.7%, LPS-treated ; -73.6±3.3%). In both
cases, the inhibitory activity was decreased by the
treatment of AM with thrombin.
IL-1 in AM Supernatants
The amount of IL-1 in the AM supernatants from
control and bleomycin-treated rats was measured by
enzyme immunoassays (Fig.6). Very little IL-1 α was
present in the supernatants of both the untreated and LPS-
Fig. 4. Effects of PDGF-AA and -BB on fibroblast growth. Various
concentrations of recombinant human PDGF-AA or -BB were
added to cultures of fibroblasts from control rats with medium
containing 1% BSA, 1% FCS, or 2% FCS. After culturing for 3 days,
FGA was determined as described in the Materials and Methods.
The FGA is expressed as the percentage increase from the value of
the medium control culture. Columns and bars show the means
and SD of values for 3 rats.
Fig. 5. Fibroblast growth-stimulating activity in the supernatants of
AM from bleomycin-treated rats. AM were cultured with medium
alone, medium + LPS (1 μg/ml), or medium + purified rat thrombin
(1 U/ml or 10 U/ml) for 24 h. Samples of the AM supernatants
were added to the cultures of fibroblasts from the lungs of control
and bleomycin-treated rats at a concentration of 10%. After culturing
for 3 days, their effects on fibroblast growth were assayed as
described in Materials and Methods. The FGA is expressed as the
percentage increase from the value of the medium control culture.
Columns and bars show the means and SD of values for 3 rats.
*Significantly different from the value cultured in medium alone by
Student's t-test (p<0.01).
**Significantly different from the values cultured in medium alone
(p<0.01) and in the supernatant of untreated AM (p<0.05) by
Student's t-test.
Fig.6. IL-1 α in the supernatants of AM from control and
bleomycin-treated rats. The amount of IL-1 α was measured by
enzyme immunoassay. Columns and bars show the means and SD
of values for three rats.
*Significantly different from the value cultured in the supernatant
of untreated AM by Student's t-test (p<0.01).
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or thrombin-treated AM from control rats. Higher levels of
IL-1 α were detected in the AM supernatants from
bleomycin-treated rats than in those from control rats.
The supernatant of AM treated with LPS showed
significantly higher IL-1 α levels than the untreated AM,
but thrombin did not increase the release of IL-1 α from
AM. IL-1 β was not detected in the supernatants of AM
from control or bleomycin-treated rats (data not shown).
DISCUSSION
The results of this study demonstrated that thrombin
stimulates AM to produce fibroblast growth-stimulating
factor(s), and that one of these factors is PDGF-AA.
Thrombin activity has been suggested to be increased in
the lungs of patients with fibrotic lung diseases, because
increased levels of procoagulant activity in BAL fluid and
excessive fibrin deposition have been observed in the
injured lungs of patients with IPF and ARDS and in animal
models(1-5, 7). In fact, increased thrombin activity has
been detected in the BAL fluid from rats with bleomycin-
induced lung injury and from patients with scleroderma
(15, 16). Thus, thrombin may be increased and activated
in the injured lungs of animal models and in patients with
fibrotic lung diseases, and may play a critical role in the
development of fibrosis.
Thrombin has been shown by a number of laboratories
to be mitogenic to fibroblasts, epithelial and endothelial
cells, T lymphocytes, monocytes, and certain macrophage-
like cell lines in vitro (8-14). Thrombin has also been
shown to stimulate endothelial cells, epithelial cells, and
fibroblasts to produce a variety of inflammatory cytokines
including PDGF (16, 25, 26), transforming growth factor-β
(27), and IL-1(28). The present study observed the first
evidence that thrombin can stimulate AM to produce
PDGF.
PDGF is an important fibrogenic cytokine, and its
primary source may be AM in the development of
pulmonary fibrosis. AM from IPF patients spontaneously
released PDGF at a level higher than that released by AM
from normal patients(29), and a strong expression of
PDGF mRNA was observed in AM from patients with IPF
(30). The mechanism of PDGF production by AM in
fibrotic lung diseases is not yet known, but the present
findings indicate that thrombin may play a role in PDGF
production by AM.
PDGF, a 30-kD protein, is a disulfide-linked homodimer
or heterodimer of two peptides (AA, BB or AB). The
biologic significance of the different forms is known to
differ in their mitogenic potency in some culture systems.
PDGF-BB is consistently mitogenic, but the mitogenicity
of PDGF-AA appears to vary among species. For normal
rat lung fibroblasts, PDGF-BB is more potent than PDGF-
AB, and PDGF-AB far exceeds the growth-promoting
potential of PDGF-AA(31). Swiss 3 T 3 cells have been
shown to respond mitogenically to all PDGF isoforms(31),
and similar responses to the isoforms PDGF-AA, BB, and
AB were observed in human fetal and adult lung fibro-
blasts(32). Our present results regarding the mitogenic
response of PDGF isoforms on fibroblasts showed that
their responses differed depending on the serum
conditions (Fig.4). After culturing in medium with FCS,
PDGF-BB was more proliferative to fibroblasts than
PDGF-AA, but PDGF-AA was more proliferative under
serum-free conditions.
The present results indicate that PDGF-AA is released
by AM stimulated with thrombin and induces fibroblast
growth in vitro. AM are capable of releasing all three
PDGF isoforms(31). Nagaoka et al. reported that both
PDGF-AA and -BB mRNA levels are markedly increased
in AM from patients with IPF compared with control
patients, and that this increase is 10-fold higher for PDGF-
BB compared with PDGF-AA (30). Bonner et al. showed
that rat AM stimulated with chrysotile asbestos or
carbonyl iron spheres secrete all PDGF isoforms when
cultured in rabbit platelet-poor plasma, but that PDGF-BB
is the most predominant isoform (31). Thus, previous
findings that the predominant PDGF isoform released
from AM is PDGF-BB differ from our results. This
discrepancy may be explained by the following two
possibilities. First, PDGF isoforms produced by AM may
differ depending on the kind of stimuli used ; thrombin
selectively stimulates the production of PDGF-AA.
Second, PDGF isoforms released from AM with or
without the stimulation of thrombin may vary depending
on the in vitro culture conditions. Similarly, the different
proliferative effects of PDGF isoforms may also vary
under differing serum conditions. In this study, AM were
stimulated with thrombin in serum-free medium because
various thrombin inhibitors such as α 1-protease inhibitor,
antithrombin III, and α 2 macroglobulin are present in
serum (33). The elucidation of the PDGF isoforms
released by AM activated in the lungs of fibrotic lung
models requires further study.
The supernatant of AM stimulated with thrombin
showed the FGA not only to fibroblasts from control rats
but also to those from bleomycin-treated rats (Fig.1).
Moreover, human PDGF-AA produced the same response
mitogenically for fibroblasts from both control and
bleomycin-treated rats (data not shown). These results
suggest that fibroblasts in lungs injured by bleomycin
may respond to PDGF released from AM. However, the
supernatant of AM from bleomycin-treated rats also
contained an inhibitory activity for fibroblast growth and
increased levels of IL-1 α. The stimulation of AM with
thrombin decreased the inhibitory activity but had no
effect on IL-1 α release (Figs.5 and 6). We found previ-
ously that AM from bleomycin-treated rats at an early
stage produced IL-1 α at both protein and mRNA levels,
which corresponded to FGA in AM (34). Accordingly, we
suggested that the inhibitory activity may be due to IL-1 α,
and that this was partly decreased by the activity of
fibroblast growth-stimulating factor(s) such as PDGF
released from thrombin-stimulated AM. Although AM
from rats with bleomycin-induced lung injury produced IL-
1 α consistently in cultures in vitro, the continuous
stimulation of AM by thrombin may be necessary for
PDGF release. As reported previously(15), however,
increased levels of thrombin activity were detected in the
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lungs of bleomycin-treated rats, suggesting that AM may
be stimulated with thrombin and release PDGF in the
injured tissues.
Thrombin is known to induce fibroblast growth directly.
This study demonstrated another mechanism, namely that
thrombin induces fibroblast growth through the induction
of PDGF production by AM. Further study is necessary to
clarify whether this evidence applies to fibroblast growth
and the development of pulmonary fibrosis in fibrotic lung
diseases.
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